丁苯酞对实验性自身免疫性脑脊髓炎小鼠na+k+atpase、erk12表达的影响

《丁苯酞对实验性自身免疫性脑脊髓炎小鼠na+k+atpase、erk12表达的影响》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、授予单位代码誦９１１３８１４钟夫遂ＨｅｂｅｉＭｅｄｉｃａｌＵｎｉｖｅｒｓｉｔｙ？硕±学位论文在职科学学位了苯駄对实验性自身免疫巧脑脊髓炎小鼠Ｎａ＋／Ｋ＋ＡＴＰａｓｅ、ＥＲＫ１／２表达的影响学位申请人：张瑞丹导师：檀国军教授专业：神经病学二级学院：第二医院２０１５年１０月河北医科大学学位论文使用授权及巧识产权归属承语本学位论文在导师）的指导下，由本人独立完成。（或指导小组本学位论文研究所获得的研究成果，其知识产权归河北医科大学所、公开和使用有。河北医科大学有权对本学位论文进行交

2、流。凡发表一与学位论文主要内容相关的论文署名为单位河北医科大学，，第试验材料、申报的专利等知识产权均归河北医科大学所、原始数据。否则。．的７、有，承担相应法律责任：子．－－扣研究生签名：３导师签章级学院领导盖章记ｔ錢＾謗畏Ｉ＇’毎楚年月＼霞河北匿科大学研究生学位论文独创性声明本论文是在导师指导下进行的研究工作及取得的研究成果，除了文中特别加标注和致谢等内容外，文中不包含其他人已经发表或撰写的研究成果。，指导教师对此进行了审定本论文由本人独立撰写。，文责自负研究生签名：漱戴导师签章＾年月日目录中文摘

3、要··············································································1英文摘要··············································································4英文缩写··············································································9研究论文丁苯酞对实验性自身免疫性脑脊髓炎小鼠Na+/K+ATPase、ER

4、K1/2表达的影响前言··············································································10材料与方法·····································································11结果··············································································18附图································

5、··············································21附表··············································································23讨论··············································································26结论·····································································

6、·········29参考文献········································································30综述丁苯酞的神经保护作用及机制研究进展·······························33致谢····················································································41个人简历··················································

7、····························42中文摘要丁苯酞对实验性自身免疫性脑脊髓炎小鼠Na+/K+ATPase、ERK1/2表达的影响摘要目的：多发性硬化（multiplesclerosis,MS）是一种中枢神经系统常见的慢性炎症性脱髓鞘疾病，以髓鞘脱失、轴索病变、炎性细胞浸润、神经胶质细胞增生和进行性神经功能障碍为主要特点，好发于青年人，目前尚缺乏有效的治疗方法，致残率高。丁苯酞（dl-3n-butlphalide,NBP)是我国脑血管疾病治疗领域中第一个拥有自主知识产权的国家级一类新药，是首个在国际上通过作用于多个靶点及多个环节来治疗缺血

8、性脑卒中的一种创新药物。临床药效学研究